Developed for use by clinicians and non-clinicians involved in daily design of pharmacy benefit programs.
Specialty Pharmacy Market Overview – Market Shakeout Continuing into 2018 As the specialty drug spend grows, specialty pharmacies are playing an increasingly larger role in access and delivery of medications and services. The specialty pharmacy market, while dominated by a few large companies, has an increasing number of participants. AMI’s annual report, Specialty Pharmacy Market […]
Amber Specialty Pharmacy leads patient satisfaction. Amber Pharmacy, a wholly owned subsidiary of Hy-Vee, is the No. 1 ranked specialty pharmacy in the U.S. for patient satisfaction with pharmacy employees, according to a recent Zitter Health Insights survey. The survey assessed numerous aspects of patient satisfaction and garnered responses from more than 3,000 patients across 38 […]
Employer Perspectives Specialty Drug Step-Therapy Program Evaluation American Health and Drug Benefits, September 2016 Vol 9, No 6 – Industry Trends Matthew Harman, PharmD, MPH, Director, Clinical Pharmacy Strategies Employers Health, Columbus, OH F. Randy Vogenberg, PhD, RPh, Strategic Advisor and Co–Project Leader, Midwest Business Group on Health National Employer Biologics & Specialty Drug Initiative […]
VA Extending Hepatitis C Therapy as its drug spend for the disease increases rapidly. The department last year allocated $696 million for new hepatitis C drugs, accounting for 17 percent of the VA’s total pharmacy budget. In fiscal 2016, which began Oct. 1, 2015, the VA expects to spend about $1 billion on hepatitis C […]
Specialty Drug Spend Under the Medical Benefit — Biologic, biotechnology based, rare disease or high cost pharmaceuticals—collectively known as specialty drugs—can be covered under the pharmacy benefit, the medical benefit, or both depending on the plan sponsors’ benefit design required of the payor. On average, up to 50% of specialty drugs are covered under the […]
Future of Specialty Pharmacy – Recent events involving Valeant and Philidor have caused an uproar in the marketplace along with the Turing Pharmaceutical (and generics) mess around pricing. Now the NY Times casts the light on Horizon and Linden illustrating the bad without much good around stakeholder relationships that pharma firms have utilized. Due to the evolution […]
Specialty Drug Wave Hitting Medical and Pharmacy Plans Harder: Trends versus reliable benefit strategy to handle the impact through 2020?The U.S. now has two different markets resulting from implementation of the Affordable Care Act (ACA) and resultant trends. Related to specialty or biological drugs, public sector CMS’s forecast of drug spending is somewhat counterintuitive, given […]